Back to top
more

Astellas Pharma (ALPMY)

(Delayed Data from OTC)

$12.19 USD

12.19
307,999

+0.29 (2.44%)

Updated Sep 18, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ALPMY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Astellas Pharma Inc falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents 2,414 2,982 2,765 2,988 3,008
Receivables 3,629 3,352 3,312 3,218 3,400
Notes Receivable 0 0 0 0 0
Inventories 1,647 1,311 1,255 1,478 1,385
Other Current Assets 222 250 238 177 166
Total Current Assets 7,912 7,894 7,568 7,861 7,959
Net Property & Equipment 1,945 2,154 2,205 2,384 2,464
Investments & Advances 824 831 835 928 724
Other Non-Current Assets 133 182 244 306 312
Deferred Charges 302 633 593 488 485
Intangibles 12,401 6,698 7,594 8,428 9,229
Deposits & Other Assets 123 77 78 89 93
Total Assets 23,640 18,470 19,118 20,483 21,268
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 1,226 1,054 1,072 1,124 1,578
Current Portion Long-Term Debt 3,128 0 0 0 0
Current Portion Capital Leases 646 1,354 1,516 1,335 3,172
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 255 39 265 76 37
Other Current Liabilities 3,259 3,011 2,782 2,802 2,542
Total Current Liabilities 8,515 5,459 5,635 5,337 7,328
Mortgages 0 0 0 0 0
Deferred Taxes/Income 340 45 48 164 254
Convertible Debt 0 0 0 0 0
Long-Term Debt 2,965 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1,250 1,628 1,467 2,495 1,859
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 13,070 7,132 7,148 7,996 9,440
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 682 774 844 928 945
Capital Surplus 1,219 1,363 1,471 1,602 1,628
Retained Earnings 5,360 6,828 7,740 8,588 8,311
Other Equity 3,532 2,561 2,029 1,508 1,009
Treasury Stock 224 189 114 139 66
Total Shareholder's Equity 10,569 11,338 11,970 12,488 11,827
Total Liabilities & Shareholder's Equity 23,640 18,470 19,118 20,483 21,268
Total Common Equity 10,569 11,338 11,970 12,488 11,827
Shares Outstanding 1,809.60 1,809.60 1,835.80 1,861.70 1,888.80
Book Value Per Share 5.84 6.27 6.52 6.71 6.26

Fiscal Year End for Astellas Pharma Inc falls in the month of March.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 2,167 2,414 1,941 2,509 4,401
Receivables 3,840 3,629 3,440 3,482 3,484
Notes Receivable 0 0 NA NA 0
Inventories 1,639 1,647 1,537 1,474 1,462
Other Current Assets 294 222 223 241 272
Total Current Assets 7,940 7,912 7,141 7,706 9,617
Net Property & Equipment 1,982 1,945 1,965 2,046 2,123
Investments & Advances 851 824 797 819 807
Other Non-Current Assets 141 133 142 150 168
Deferred Charges 347 302 290 306 735
Intangibles 12,460 12,401 12,514 13,361 6,907
Deposits & Other Assets 187 123 58 60 70
Total Assets 23,907 23,640 22,907 24,447 20,425
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 NA NA 0
Accounts Payable 1,108 1,226 1,023 1,016 1,011
Current Portion Long-Term Debt 3,517 3,128 2,769 2,874 2,256
Current Portion Capital Leases 667 646 684 681 730
Accrued Expenses 0 0 NA NA 0
Income Taxes Payable 190 255 237 216 119
Other Current Liabilities 3,310 3,259 3,132 3,232 3,123
Total Current Liabilities 8,792 8,515 7,845 8,020 7,238
Mortgages 0 0 NA NA 0
Deferred Taxes/Income 288 340 476 639 48
Convertible Debt 0 0 NA NA 0
Long-Term Debt 2,836 2,965 3,154 3,264 365
Non-Current Capital Leases 0 0 NA NA 0
Other Non-Current Liabilities 1,262 1,210 1,212 1,252
Minority Interest (Liabilities) 0 0 NA NA 0
Total Liabilities 13,178 13,070 12,685 13,135 8,903
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 NA NA 0
Common Stock (Par) 659 682 700 711 752
Capital Surplus 1,169 1,219 1,244 1,257 1,319
Retained Earnings 5,016 5,360 5,703 6,103 6,457
Other Equity 4,132 3,532 2,807 3,478 3,246
Treasury Stock 247 224 232 237 252
Total Shareholder's Equity 10,729 10,569 10,222 11,311 11,522
Total Liabilities & Shareholder's Equity 23,907 23,640 22,907 24,447 20,425
Total Common Equity 10,729 10,569 110,221 111,310 11,522
Shares Outstanding 1,809.60 1,809.60 1,809.60 1,809.60 1,809.60
Book Value Per Share 5.93 5.84 60.91 61.51 6.37